ArticleJournal of translational medicine2025
SET8 modulates prognosis and radiotherapeutic efficacy by regulating radiation-induced migration in lung adenocarcinoma.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of prediction model for intrapulmonary metastasis in lung adenocarcinoma based on machine learning.Journal of thoracic disease · 2026Article
- Expression of PIEZO1 in lung adenocarcinoma correlates with PD-L1 expression, cell migration, and poor prognosis: an exploratory study.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTumor migration in lung adenocarcinoma (LUAD) contributes to a poor prognosis by allowing malignant cells to escape the localized effects of radiotherapy, diminishing its overall efficacy. This study investigated the role of SET8, a methyltransferase, in LUAD migration and radiotherapy.
methodsIn vitro experiments, including CRISPR/Cas9-mediated SET8 knockout, wound healing assays, and transwell migration assays, were used to assess the impact of SET8 on radiation-induced migration in LUAD cells. Bioinformatics analyses, such as differential expression analysis, clustering, functional enrichment, and CpG island methylation analysis, were performed using LUAD patient data from TCGA to examine the broader relationship between SET8, LUAD migration, and prognosis. Statistical methods, including Cox regression and LASSO regression, were employed to establish a prognostic model for radiotherapy outcomes, and drug sensitivity analysis was used to identify potential therapeutic agents.
resultsIonizing radiation induced migration in LUAD cells, coupled with altered SET8 expression. SET8 was found to engage in IR-induced migration through the PTTG1-PI3K-AKT signaling axis. Furthermore, elevated SET8 expression was more prevalent in LUAD patients with metastasis and correlated with adverse prognosis. Under equivalent X-ray irradiation doses, SET8 depletion significantly inhibited the migratory capability of LUAD cells. Finally, SET8-associated migration genes could predict the survival rate, radiation responsiveness, and drug sensitivity of radiotherapy patients.
conclusionSET8 facilitates radiation-induced migration in LUAD through the PTTG1-PI3K-AKT pathway, and SET8-associated genes may act as valuable markers for predicting radiotherapeutic efficacy in LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.